Doctors blast Biogen Alzheimer approval as ‘regulatory failure’
The New England Journal of Medicine opinion piece is another sign of persistent furor over the agency’s decision.
The New England Journal of Medicine opinion piece is another sign of persistent furor over the agency’s decision.
The nation’s haul of 11 gold medals is lifting everything from real estate stocks to the shares of seafood…
Flush with cash from an IPO, Kuaishou is cranking up spending to close the gap with ByteDance, more than…
The company added 1.54 million customers in the second quarter, above the 1.12 million forecast by analysts, but it’s…
Last week marked a watershed for technology startups in India, as a record bout of fundraising shifted attention to…
The envisaged listing of Kioxia, formerly known as Toshiba Memory Holdings Corp., comes as robust demand for semiconductors is…
The shareholder revolt, led by foreign activist investors, against the approval of Nagayama as chairman has added to the…
The cascade of failures across the web turned a mere “service configuration” into a global outage that hit large…
A move by the U.S. private equity firm to purchase a stake of New Zealand Rugby’s commercial operations has…
The last time that the BOJ did not make any ETF purchases for a whole month was in December…